AstraZeneca PLC Form 6-K Filing Summary

This report details the US FDA approval of AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, particularly those with an ESR1 mutation detected after initial AI and CDK4/6 inhibitor therapy. The approval, based on the SERENA-6 Phase III trial, showed a significant 56% reduction in the risk of disease progression or death with the Etcamah combination compared to standard care. This represents a new treatment strategy for a significant patient population, addressing the challenge of endocrine resistance. The FDA also approved a companion diagnostic test for ESR1 mutations. Etcamah is already approved in over 30 countries. The filing also provides background on breast cancer statistics, the significance of ESR1 mutations, and details about the SERENA-6 trial and Etcamah's mechanism of action.